Rep. Kelly Morrison Sells Thermo Fisher Scientific Inc. (NYSE:TMO) Shares

Key Points

• Representative Kelly Morrison sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO), disclosing a sale of between $15,001 and $50,000 on August 19th.
• Thermo Fisher's stock currently has a market cap of $181.06 billion, and its shares recently traded at $479.48, down $11.93 on the day.
• The company announced a quarterly dividend of $0.43 per share, which will be paid on October 15th, representing an annualized dividend yield of 0.4%.

Representative Kelly Morrison (D-Minnesota) recently sold shares of Thermo Fisher Scientific Inc. NYSE: TMO. In a filing disclosed on September 11th, the Representative disclosed that they had sold between $15,001 and $50,000 in Thermo Fisher Scientific stock on August 19th. The trade occurred in the Representative's "TRUST 2" account.

Representative Kelly Morrison also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Verizon Communications NYSE: VZ on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 8/19/2025.
• Sold $15,001 - $50,000 in shares of Accenture NYSE: ACN on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Accenture NYSE: ACN on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Thermo Fisher Scientific NYSE: TMO on 8/19/2025.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $11.93 during trading on Friday, hitting $479.48. 1,543,232 shares of the company's stock were exchanged, compared to its average volume of 1,555,589. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The business has a 50-day simple moving average of $466.86 and a 200-day simple moving average of $451.08. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77. The stock has a market capitalization of $181.06 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 2.62 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter last year, the company posted $5.37 earnings per share. The firm's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TMO. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $490.00 to $550.00 in a report on Thursday. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. William Blair began coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Finally, HSBC reiterated a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $592.24.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company's stock worth $13,700,154,000 after acquiring an additional 309,207 shares during the last quarter. Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $2,264,615,000. Franklin Resources Inc. lifted its holdings in shares of Thermo Fisher Scientific by 11.3% in the 2nd quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company's stock worth $1,985,759,000 after acquiring an additional 498,238 shares during the last quarter. Amundi lifted its holdings in shares of Thermo Fisher Scientific by 5.9% in the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after acquiring an additional 168,197 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Thermo Fisher Scientific by 2.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company's stock worth $1,216,612,000 after buying an additional 74,971 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last ninety days. 0.33% of the stock is owned by corporate insiders.

About Representative Morrison

Kelly Morrison (Democratic Party) is a member of the U.S. House, representing Minnesota's 3rd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Morrison (Democratic Party) is running for re-election to the U.S. House to represent Minnesota's 3rd Congressional District. She declared candidacy for the 2026 election. Kelly Morrison was born in Minneapolis, Minnesota, and lives in Deephaven. Morrison earned a B.A. in history from Yale University and an M.D. from Case Western Reserve University. She completed her residency in obstetrics and gynecology at Northwestern University. Morrison's career experience includes working as a physician.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.